Dariush Etemadmoghadam

24.4k total citations · 2 hit papers
23 papers, 3.1k citations indexed

About

Dariush Etemadmoghadam is a scholar working on Molecular Biology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, Dariush Etemadmoghadam has authored 23 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Reproductive Medicine and 11 papers in Cancer Research. Recurrent topics in Dariush Etemadmoghadam's work include Ovarian cancer diagnosis and treatment (12 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer-related Molecular Pathways (5 papers). Dariush Etemadmoghadam is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer-related Molecular Pathways (5 papers). Dariush Etemadmoghadam collaborates with scholars based in Australia, United States and United Kingdom. Dariush Etemadmoghadam's co-authors include David D.L. Bowtell, Anna DeFazio, Joshy George, Sián Fereday, Stephen B. Fox, Ahmed A. Ahmed, Nadia Traficante, Richard W. Tothill, Robert Brown and Izhak Haviv and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Dariush Etemadmoghadam

23 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

2008 1.0k citations Richard W. Tothill, Anna V. Tinker et al. Clinical Cancer Research profile →
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

2010 508 citations Ahmed A. Ahmed, Dariush Etemadmoghadam et al. The Journal of Pathology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dariush Etemadmoghadam Australia	18	1.7k	1.1k	1.1k	1.0k	444	23	3.1k
Sián Fereday Australia	15	1.4k 0.8×	1.6k 1.4×	1.4k 1.2×	994 1.0×	318 0.7×	29	3.1k
Steven McKinney Canada	18	1.2k 0.7×	503 0.4×	1.2k 1.1×	977 1.0×	310 0.7×	30	2.9k
Melanie Trivett Australia	13	1.2k 0.7×	494 0.4×	1.0k 0.9×	695 0.7×	382 0.9×	16	2.4k
Bethan Powell United States	6	1.8k 1.1×	663 0.6×	1.6k 1.5×	594 0.6×	339 0.8×	10	2.9k
Elisabeth Müller‐Holzner Austria	38	2.1k 1.3×	506 0.4×	1.5k 1.4×	962 1.0×	308 0.7×	99	4.3k
Gulisa Turashvili Canada	29	1.9k 1.2×	301 0.3×	1.2k 1.2×	1.4k 1.4×	519 1.2×	109	3.9k
Michael S. Anglesio Canada	32	1.5k 0.9×	1.8k 1.6×	652 0.6×	737 0.7×	368 0.8×	71	3.6k
Anne M. Øyan Norway	37	1.6k 1.0×	254 0.2×	809 0.7×	769 0.8×	410 0.9×	75	2.9k
Barry R. Davies United Kingdom	33	2.1k 1.3×	238 0.2×	1.0k 0.9×	584 0.6×	735 1.7×	99	3.4k
Yusuke Nakamura Japan	27	1.5k 0.9×	206 0.2×	773 0.7×	627 0.6×	352 0.8×	84	2.7k

Countries citing papers authored by Dariush Etemadmoghadam

Since Specialization

Citations

This map shows the geographic impact of Dariush Etemadmoghadam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dariush Etemadmoghadam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dariush Etemadmoghadam more than expected).

Fields of papers citing papers by Dariush Etemadmoghadam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dariush Etemadmoghadam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dariush Etemadmoghadam. The network helps show where Dariush Etemadmoghadam may publish in the future.

Co-authorship network of co-authors of Dariush Etemadmoghadam

This figure shows the co-authorship network connecting the top 25 collaborators of Dariush Etemadmoghadam. A scholar is included among the top collaborators of Dariush Etemadmoghadam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dariush Etemadmoghadam. Dariush Etemadmoghadam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Portman, Neil, Kristine J. Fernandez, Christine U. Lee, et al.. (2021). Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. npj Breast Cancer. 7(1). 111–111. 15 indexed citations

Mileshkin, Linda, Andrew Pattison, Shiva Balachander, et al.. (2020). Identifying biomarkers to guide immunotherapy treatment of cancer of unknown primary.. Journal of Clinical Oncology. 38(15_suppl). e15252–e15252. 3 indexed citations

Etemadmoghadam, Dariush, C. Elizabeth Caldon, George Au‐Yeung, et al.. (2018). 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. Gynecologic Oncology. 151(2). 327–336. 27 indexed citations

Au‐Yeung, George, Walid J. Azar, Thomas J. Mitchell, et al.. (2016). Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research. 23(7). 1862–1874. 100 indexed citations

DeFazio, Anna, Dariush Etemadmoghadam, Catherine J. Kennedy, et al.. (2016). Abstract A25: BRAFV600E mutations in serous ovarian cancer and response to the BRAF inhibitor, dabrafenib.. Clinical Cancer Research. 22(2_Supplement). A25–A25. 1 indexed citations

Karst, Alison M., Natalie Vena, Azra H. Ligon, et al.. (2013). Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube–Derived High-Grade Serous Ovarian Cancers. Cancer Research. 74(4). 1141–1152. 132 indexed citations

George, Joshy, Kathryn Alsop, Dariush Etemadmoghadam, et al.. (2013). Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations. Clinical Cancer Research. 19(13). 3474–3484. 67 indexed citations

Etemadmoghadam, Dariush, George Au‐Yeung, Meaghan Wall, et al.. (2013). Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1 -Amplified Ovarian Cancer. Clinical Cancer Research. 19(21). 5960–5971. 90 indexed citations

Etemadmoghadam, Dariush, Barbara A. Weir, George Au‐Yeung, et al.. (2013). Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proceedings of the National Academy of Sciences. 110(48). 19489–19494. 157 indexed citations

10.

Baumbusch, Lars O., Åslaug Helland, Yun Wang, et al.. (2013). High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. PLoS ONE. 8(1). e54356–e54356. 17 indexed citations

11.

Emmanuel, Catherine, Catherine J. Kennedy, Rosemary L. Balleine, et al.. (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PLoS ONE. 6(3). e17617–e17617. 31 indexed citations

12.

Ahmed, Ahmed A., Dariush Etemadmoghadam, Jillian Temple, et al.. (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. The Journal of Pathology. 221(1). 49–56. 508 indexed citations breakdown →

13.

Cowin, Prue A., Michael S. Anglesio, Dariush Etemadmoghadam, & David D.L. Bowtell. (2010). Profiling the Cancer Genome. Annual Review of Genomics and Human Genetics. 11(1). 133–159. 33 indexed citations

14.

Ahmed, Ahmed A., Zhen Lü, Nicholas B. Jennings, et al.. (2010). SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer. Cancer Cell. 18(2). 109–121. 105 indexed citations

15.

Etemadmoghadam, Dariush, Joshy George, Prue A. Cowin, et al.. (2010). Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer. PLoS ONE. 5(11). e15498–e15498. 74 indexed citations

16.

Gorringe, Kylie L., Joshy George, Michael S. Anglesio, et al.. (2010). Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer. PLoS ONE. 5(9). e11408–e11408. 71 indexed citations

17.

Gewinner, Christina, Zhigang C. Wang, Andrea L. Richardson, et al.. (2009). Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling. Cancer Cell. 16(2). 115–125. 365 indexed citations

18.

Tothill, Richard W., Anna V. Tinker, Joshy George, et al.. (2008). Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research. 14(16). 5198–5208. 1041 indexed citations breakdown →

19.

Ahmed, Ahmed A., Dariush Etemadmoghadam, Anna DeFazio, et al.. (2007). High resolution melting for mutation scanning of TP53exons 5–8. BMC Cancer. 7(1). 168–168. 119 indexed citations

20.

Kanellis, John, Roger J. Bick, Gabriela García, et al.. (2004). Stanniocalcin-1, an inhibitor of macrophage chemotaxis and chemokinesis. American Journal of Physiology-Renal Physiology. 286(2). F356–F362. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact